The case for & against
Bull & Bear analysis
Bearish
OpGen, Inc. (NASDAQ: OPGN), now repositioned as CapForce Inc., operates in the biotechnology space specializing in precision medicine diagnostics, particularly focused on combating antimicrobial resistance (AMR) and infectious diseases. The company is transitioning to a new identity as a digital investment banking firm while still leveraging its existing diagnostics products. Notably, OpGen is advancing efforts in market segments with pressing health concerns, such as AMR, through innovative solutions like the Univero platform and Acuitus AMR gene panel.
Bull says
- ↑Q1 2023 revenue rose 94% YoY to $913K via collaborations
- ↑Univero UTI panel achieved 96.4% sensitivity, boosting FDA clearance odds
- ↑Fisher Healthcare tie-up opens hundreds of U.S. leads for sales
- ↑Q2 2023 operating expenses fell to $5.9M from $6.2M
- ↑New contracts could add $1.5M in annualized revenue
- ↑Favorable earnings outlook revisions and cost discipline support valuation
Bear says
- ↓Cash fell to $3.2M as of June 30, insufficient post-Sep 2023
- ↓2022 operating costs jumped to $37.2M from $27.6M in 2021
- ↓FDA approval for UTI panel may slip into 2024, delaying revenues
- ↓Revenue relies on partnerships; signing delays risk 2023 guidance
- ↓Competition from Qiagen, Cepheid, and Illumina threatens market share
- ↓High cash burn and liquidity risk cloud financial outlook
Earnings Call · Q2 2022 · Mgmt. Guidance
Updated 09-11-2026neutral
Transcript signals
Bull points
- We are excited to announce our second quarter 2022 revenue of close to $1 million. We closed out the second quarter with approximately $967,000 of revenue, a 19% increase from this time last year, while revenue in the first half of 2022 added up to $1.4 million, compared to $1.6 million in the six-month period of 2021.
- The increase in revenue in the second quarter is primarily due to a significant increase in product sales, which have increased by approximately 582,000, or a 189% increase year over year.
- Increased revenues, improved gross margins, and significantly reduced operating expenses on the R&D and G&A side have all contributed to this much improved result.
Bear points
- we ended the first half of 2022 with approximately $16.6 million, a decrease compared to our cash position at the end of 2021 of $36.1 million.
- We anticipate continuing that track record this year at an expected net cash consumption of around $5 to $6 million per quarter from our operations, following the recently announced restructuring of our EIB debt, we expect to see an additional cash outflow of approximately $700,000 per month.
- places like Singapore, suffering from, you know, late phases of COVID-related restrictions.
Read full transcript analysis ›